Orca-T

Phase I Trial for Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation From an HLA-Mismatched Donor (7/8) With Orca-T

What's the purpose of the trial?

The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis.
Trial status

Not yet accepting

Phase
Phase 1
Enrollment
24
Last Updated
2 weeks ago
Am I Eligible

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Orca-T is a T cell therapy made from stem and T cells. Orca-T is made from allogeneic donors, and is specialized to try and minimize allogeneic transplant side effects. 
  • Ruxolitinib is a tyrosine kinase inhibitor in development for the treatment of several different blood cancers.
  • Tacrolimus is an immunosuppressive medication used to help prevent rejection in patients who have had a transplant.

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.